Zhejiang Orient Gene Biotech Co., Ltd. Class A

As of June 30, 2026, Zhejiang Orient Gene Biotech Co., Ltd. Class A carries a market capitalization of 3.60B, placing it among publicly traded companies globally. Its enterprise value stands at 1.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Zhejiang Orient Gene Biotech Co., Ltd. Class A has 201.60M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Zhejiang Orient Gene Biotech Co., Ltd. Class A maintains a current ratio of 3.38, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Zhejiang Orient Gene Biotech Co., Ltd. Class A recorded 46.19M in income tax expense.

As of the close on October 22, 2026, Zhejiang Orient Gene Biotech Co., Ltd. Class A's stock has declined approximately 29.95% over the past 52 weeks. The 50-day moving average sits at 18.95, while the 200-day moving average is 21.43.

As of June 30, 2026, Zhejiang Orient Gene Biotech Co., Ltd. Class A holds 2.39B in cash and equivalents against 444.40M in total debt, resulting in a net debt position of -1.99B. Total book value stands at 5.75B, with working capital of 2.12B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Zhejiang Orient Gene Biotech Co., Ltd. Class A paid dividends of 0.02 per share.

Zhejiang Orient Gene Biotech Co., Ltd. Class A's most recent stock split took place on June 26, 2023 with a 5:6 split ratio.